Advertisement

Antibiotic Use in Hospitals in the United States SCOPE-MMIT Antimicrobial Surveillance Network

  • Amy Pakyz
  • Ron Polk

Abstract

There are few recent published multihospital analyses of antibiotic use in the United States. This is due to the difficulty in acquiring antibiotic use data, especially in acquiring measures of antibiotic use that are not based on antibiotic purchases but actual consumption (Fridkin et al. 1999, Fridkin and Gaynes 1999, Carling et al. 1999, Centers for Disease Control and Prevention 2003). Measures of antibiotic use based on purchase data are indirect and dependent on purchasing variations, manufacturer drug pricing, and vendor discounts (Madaras-Kelly 2003).

Keywords

Antibacterial Drug Surveillance Network National Nosocomial Infection Surveillance Antibiotic Cost Lactamase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carling PC, Fung T, Coldiron JS (1999) Parenteral antibiotic use in acute-care hospitals: A standardized analysis of fourteen institutions. Clin Infect Dis 29:1189–1196.CrossRefPubMedGoogle Scholar
  2. Centers for Disease Control and Prevention (2003) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 31:481–498.Google Scholar
  3. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo, G (2000) An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data. Theoretical considerations and practical applications. Eur J Clin Pharmacol 56:513–517.CrossRefPubMedGoogle Scholar
  4. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream inflections in United States hospitals: A three-year analysis. Clin Infect Dis 29:239–344.CrossRefPubMedGoogle Scholar
  5. Fridkin SK, Gaynes RP (1999) Antimicrobial resistance in intensive care units. Clin Chest Med 20:303–316.CrossRefPubMedGoogle Scholar
  6. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynor RP, Tenover FC (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29:245–252.CrossRefPubMedGoogle Scholar
  7. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, Gaynes RP, McGowan JE Jr (2001) The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 135:175–183.PubMedGoogle Scholar
  8. Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE, Gaynes RP, and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project, and the National Nosocomial Infections Surveillance (NNIS) System Hospitals (2002a) Monitoring antimicrobial use and resistance: Comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 8:702–707.PubMedGoogle Scholar
  9. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RH, Gaynes RP, McGowan JE Jr (2002b) Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 8:697–701.PubMedGoogle Scholar
  10. Madaras-Kelly K (2003) Optimizing antibiotic use in hospitals: The role of population-based surveillance in limiting antibiotic resistance. Pharmacother 23:1627–1633.CrossRefGoogle Scholar
  11. National Nosocomial Infections Surveillance (NNIS) System Report (2001), data summary from January 1992–June 2001, Issued August 2001. Am J Infect Control 29:404–421.Google Scholar
  12. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 289:885–888.CrossRefPubMedGoogle Scholar
  13. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB (2004) Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39:497–503.CrossRefPubMedGoogle Scholar
  14. Polk RE, Letcavage J, Mahoney A, MacDougall C (2007) Adult Antibiotic Usage in 131 US hospitals: Comparison of Defined Daily Dose(DDD) to Duration of Therapy (DOT)/1000 patient days (PD). Clin Infect Dis 44:664–670.CrossRefPubMedGoogle Scholar
  15. World Health Organization Collaborating Centre for Drug Statistics Methodology http://www.whocc.no/atcddd/.

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Amy Pakyz
    • 1
  • Ron Polk
    • 2
  1. 1.School of Pharmacy, Department of PharmacyVirginia Commonwealth University, Medical College of Virginia CampusRichmondUSA
  2. 2.School of Pharmacy, Department of Pharmacy, School of Medicine, Department of Internal MedicineVirginia Commonwealth University, Medical College of Virginia CampusRichmondUSA

Personalised recommendations